Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.

Kovari, H; Surial, B; Tarr, P E; Cavassini, M; Calmy, A; Schmid, P; Bernasconi, E; Rauch, A; Wandeler, G; Ledergerber, B (2021). Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study. HIV medicine, 22(7), pp. 623-628. Wiley 10.1111/hiv.13106

[img] Text
hiv.13106.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (199kB)

OBJECTIVES

We previously demonstrated an association between tenofovir disoproxil fumarate (TDF) and chronic liver enzyme elevation in the D:A:D study. The objective of the study was to assess changes in alanine aminotransferase (ALT) levels after switching from TDF to tenofovir alafenamide (TAF).

METHODS

We included Swiss HIV Cohort Study participants who switched from TDF to TAF with two or more ALT values in the 24 months before and two or more values in the 24 months after replacing TDF with TAF. Individuals with replicating viral hepatitis were excluded. Uni- and multivariable linear mixed models were used to explore changes in ALT values associated with switching from TDF to TAF, and to assess potential modifying effects.

RESULTS

A total of 1712 participants were included, contributing 6169 ALT values before and 5482 after switching. Median (interquartile range, IQR) age was 50 (42-57) years, and 75% were male. Median (IQR) ALT was 28 (22-38) U/L before and 24 (19-32) U/L after replacing TDF with TAF. ALT values decreased by 3.7 U/L (95% confidence interval: 3.2-4.2) after the switch. The median drop was larger in patients with chronic ALT elevation (defined as two or more elevated values for ≥ 6 months) compared with patients with normal ALT values (17.8 vs. 3.3 U/L, P < 0.001). We did not identify any major effect modifications of the ALT change with any of the potential variables studied.

CONCLUSIONS

Replacing TDF with TAF in HIV-monoinfected people led to a significant decrease in ALT values. Findings were not significantly affected by known risk factors for hepatotoxicity.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Surial, Bernard, Rauch, Andri, Wandeler, Gilles

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

1464-2662

Publisher:

Wiley

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

12 May 2021 15:21

Last Modified:

05 Dec 2022 15:51

Publisher DOI:

10.1111/hiv.13106

PubMed ID:

33880839

Uncontrolled Keywords:

HIV alanine aminotransferase tenofovir alafenamide tenofovir disoproxil fumarate

BORIS DOI:

10.48350/156060

URI:

https://boris.unibe.ch/id/eprint/156060

Actions (login required)

Edit item Edit item
Provide Feedback